Histologic Transformation From NSCLC to SCLC: A Mechanism of Resistance to Osimertinib and Other Agents Targeting EGFR Mutations

Ongoing Immunotherapy Challenges Part II: Defining Benefit for Elderly Patients With NSCLC

Letter to the Editor: Previously Excluded Patients with Autoimmune Disorders, HIV, and More

PACIFIC Flooded Us with Optimism. Now What?

Bringing Lung Cancer Screening into Communities: An NHS Pilot Program’s Success

Uncommon Oncogenic Drivers in NSCLC

IMpower133: Finally Moving the Needle in SCLC

Dr. Jamie E. Chaft Discusses Emerging Data on Induction Immunotherapy for NSCLC

Ongoing Clinical Challenges: Defining Immunotherapy Benefit for Patients With NSCLC and Poor Performance Status

Explaining IMpower132: An Interview with Dr. Vassiliki A. Papadimitrakopoulou

Targeted Therapy Plus Immune Checkpoint Inhibitors: Research Opportunities, But No Improvement in Activity to Date

Neoadjuvant Nivolumab Shows Unprecedented Pathologic Complete Response for Stage III NSCLC